Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis
NCT04708782Phase 3Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2021
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of treprostinil in idiopathic pulmonary fibrosis (IPF), sponsored by United Therapeutics Corporation. Started Jun 2021; status: completed.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04708782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708782.